Extent of Lymphadenectomy and Outcome for Patients With Stage I Nonsmall Cell Lung Cancer

被引:105
作者
Varlotto, John M. [1 ]
Recht, Abram [1 ]
Nikolov, Margaret [1 ]
Flickinger, John C. [2 ]
DeCamp, Malcolm M. [3 ]
机构
[1] Beth Israel Deaconess Med Ctr, Div Radiat Oncol, Boston, MA 02215 USA
[2] Univ Pittsburgh, Sch Med, Dept Radiat Oncol, Pittsburgh, PA USA
[3] Beth Israel Deaconess Med Ctr, Div Cardiothorac Surg, Boston, MA 02215 USA
关键词
lymphadenectomy; nonsmall cell carcinoma; mediastinal dissection; lymph nodes; LYMPH-NODE DISSECTION; MEDIASTINAL LYMPHADENECTOMY; COMPLETE RESECTION; METASTASIS; RECURRENCE; SURVIVAL; LESS; CM;
D O I
10.1002/cncr.23985
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: It is uncertain whether lymphadenectomy (LA) affects overall survival (OS) or disease-free survival (DFS) rates for patients with stage I nonsmall cell lung cancer (NSCLC), as is the optimal number of lymph nodes that should be recovered. METHODS: There were 24,273 patients with stage I NSCLC diagnosed from 1992 to 2002 who were included in the Surveillance, Epidemiology, and End Results database and who underwent a definitive surgical procedure. Median follow-up was 35 months. RESULTS: For the entire population, having LA was associated with an increase in the 5-year OS rate from 41.6% to 58.4% (P<.0001) and in DFS from 58.0% to 73.09%, compared with not having LA. Outcome improved with increasing number of recovered lymph nodes, with a plateau at 11 or more lymph nodes. For patients diagnosed from 1998 to 2002 undergoing only N1 or only N2 dissections, LA was also associated with statistically significant improvements in OS in both groups and a significant difference and trend for improved DFS in the 2 groups, respectively. The maximum differences in both OS and DFS between those with no LA and those with LA occurred when 11 to 16 lymph nodes were removed for the former group or 7 to 10 lymph nodes for the latter group, respectively. CONCLUSIONS: LA was associated with increased rates of OS and DFS, compared with no LA. Our results also suggest the minimum number of recovered lymph nodes needed to see the maximum staging accuracy conferred by LA. Cancer 2009;115:851-8. (C) 2009 American Cancer Society.
引用
收藏
页码:851 / 858
页数:8
相关论文
共 27 条
[1]   Lose-specific extent of systematic lymph node dissection for non-small cell lung carcinomas according to a retrospective study of metastasis and prognosis [J].
Asamura, H ;
Nakayama, H ;
Kondo, H ;
Tsuchiya, R ;
Naruke, T .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1999, 117 (06) :1102-1111
[2]   DNA methylation markers and early recurrence in stage I lung cancer [J].
Brock, Malcolm V. ;
Hooker, Craig M. ;
Ota-Machida, Emi ;
Han, Yu ;
Guo, Mingzhou ;
Ames, Stephen ;
Gloeckner, Sabine ;
Piantadosi, Steven ;
Gabrielson, Edward ;
Pridham, Genevieve ;
Pelosky, Kristen ;
Belinsky, Steven A. ;
Yang, Stephen C. ;
Baylin, Stephen B. ;
Herman, James G. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (11) :1118-1128
[3]   Sealing of the mediastinum with a local hemostyptic agent reduces chest tube duration after complete mediastinal lymph node dissection for stage I and II non-small cell lung carcinoma [J].
Czerny, M ;
Fleck, T ;
Salat, A ;
Zimpfer, D ;
Klepetko, W ;
Wolner, E ;
Mueller, MR .
ANNALS OF THORACIC SURGERY, 2004, 77 (03) :1028-1032
[4]  
De Giacomo Tiziano, 2007, Thorac Surg Clin, V17, P217, DOI 10.1016/j.thorsurg.2007.03.008
[5]   Does the extent of lymph node dissection influence outcome in patients with stage I non-small-cell lung cancer? [J].
Doddoli, C ;
Aragon, A ;
Barlesi, F ;
Chetaille, B ;
Robitail, S ;
Giudicelli, R ;
Fuentes, P ;
Thomas, P .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2005, 27 (04) :680-685
[6]  
FUNATSU T, 1994, J THORAC CARDIOV SUR, V108, P321
[7]   Effect of number of lymph nodes sampled on outcome in patients with stage I non-small-cell lung cancer [J].
Gajra, A ;
Newman, N ;
Gamble, GP ;
Kohman, LJ ;
Graziano, SL .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (06) :1029-1034
[9]   RANDOMIZED TRIAL OF LOBECTOMY VERSUS LIMITED RESECTION FOR T1 N0 NON-SMALL-CELL LUNG-CANCER [J].
HOLMES, CE ;
RUCKDESCHEL, JC ;
JOHNSTON, M ;
THOMAS, PA ;
DESLAURIERS, J ;
GROVER, FL ;
HILL, LD ;
FELD, R ;
GINSBERG, RJ ;
MOUNTAIN, CF ;
DZUIBAN, S ;
KIELY, M ;
MCKNEALLY, MF ;
MOORES, DWO ;
RAMNES, C ;
WAGNER, H ;
BUNN, P ;
CHU, H ;
DIENHART, D ;
HAZUKA, M ;
KINZIE, J ;
SORENSEN, J ;
VANCE, V ;
BRAUN, T ;
HOPEMAN, A ;
KANE, M ;
RUSS, P ;
WHITMAN, GJR ;
FALL, SM ;
HANSEN, DP ;
HENDERSON, RH ;
MONCRIEF, CL ;
PAULING, F ;
SIMS, J ;
TELL, D ;
WISELYCARR, S ;
ABERNATHY, CM ;
CLARK, DA ;
MCCROSKEY, B ;
MOORE, G ;
MOORE, F ;
MYERS, A ;
WHITE, M ;
BROOKS, RJ ;
BULL, M ;
JOHNSON, FB ;
NEIMYR, M ;
PAQUETTE, FR ;
SACCOMANNO, G ;
LAD, T .
ANNALS OF THORACIC SURGERY, 1995, 60 (03) :615-622
[10]   Effectiveness of radical systematic mediastinal lymphadenectomy in patients with resectable non-small cell lung cancer - Results of a prospective randomized trial [J].
Izbicki, JR ;
Passlick, B ;
Pantel, K ;
Pichlmeier, U ;
Hosch, SB ;
Karg, O ;
Thetter, O .
ANNALS OF SURGERY, 1998, 227 (01) :138-144